Oramed Pharmaceuticals In... (ORMP)
Oramed Pharmaceuticals Statistics
Share Statistics
Oramed Pharmaceuticals has 40.85M shares outstanding. The number of shares has increased by -0.78% in one year.
| Shares Outstanding | 40.85M |
| Shares Change (YoY) | -0.78% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 18.76% |
| Shares Floating | 32.77M |
| Failed to Deliver (FTD) Shares | 7.88K |
| FTD / Avg. Volume | 3.12% |
Short Selling Information
The latest short interest is 248.15K, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 248.15K |
| Short % of Shares Out | 0.62% |
| Short % of Float | 0.75% |
| Short Ratio (days to cover) | 1.55 |
Valuation Ratios
The PE ratio is 16.86 and the forward PE ratio is -8.65. Oramed Pharmaceuticals's PEG ratio is -0.15.
| PE Ratio | 16.86 |
| Forward PE | -8.65 |
| PS Ratio | 69.5 |
| Forward PS | 113.9 |
| PB Ratio | 0.57 |
| P/FCF Ratio | -8.83 |
| PEG Ratio | -0.15 |
Enterprise Valuation
Oramed Pharmaceuticals has an Enterprise Value (EV) of 135.69M.
| EV / Sales | 101.26 |
| EV / EBITDA | -8.71 |
| EV / EBIT | -13.18 |
| EV / FCF | -12.86 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.32.
| Current Ratio | 3.06 |
| Quick Ratio | 3.06 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | -3.31 |
| Debt / FCF | -4.89 |
| Interest Coverage | -4.4 |
Financial Efficiency
Return on Equity is 3.37% and Return on Invested Capital is -7.21%.
| Return on Equity | 3.37% |
| Return on Assets | 2.51% |
| Return on Invested Capital | -7.21% |
| Revenue Per Employee | $103.08K |
| Profits Per Employee | $425K |
| Employee Count | 13 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -16.48% in the last 52 weeks. The beta is 1.49, so Oramed Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.49 |
| 52-Week Price Change | -16.48% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 41.69 |
| Average Volume (20 Days) | 252.43K |
Income Statement
In the last 12 months, Oramed Pharmaceuticals had revenue of 1.34M and earned 5.53M in profits. Earnings per share was 0.14.
| Revenue | 1.34M |
| Gross Profit | 1.34M |
| Operating Income | -15.77M |
| Net Income | 5.53M |
| EBITDA | -15.57M |
| EBIT | 7.13M |
| Earnings Per Share (EPS) | 0.14 |
Balance Sheet
The company has 9.05M in cash and 51.62M in debt, giving a net cash position of -42.57M.
| Cash & Cash Equivalents | 9.05M |
| Total Debt | 51.62M |
| Net Cash | -42.57M |
| Retained Earnings | -157.56M |
| Total Assets | 165.08M |
| Working Capital | 137.5M |
Cash Flow
In the last 12 months, operating cash flow was -10.29M and capital expenditures -254K, giving a free cash flow of -10.55M.
| Operating Cash Flow | -10.29M |
| Capital Expenditures | -254K |
| Free Cash Flow | -10.55M |
| FCF Per Share | -0.26 |
Margins
Gross margin is 100%, with operating and profit margins of -1176.79% and 412.31%.
| Gross Margin | 100% |
| Operating Margin | -1176.79% |
| Pretax Margin | 379.7% |
| Profit Margin | 412.31% |
| EBITDA Margin | -1162.16% |
| EBIT Margin | -1176.79% |
| FCF Margin | -787.24% |
Dividends & Yields
ORMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.93% |
| FCF Yield | -11.33% |
Analyst Forecast
Currently there are no analyst rating for ORMP.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 23, 2013. It was a backward split with a ratio of 1:12.
| Last Split Date | Jan 23, 2013 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | 5.37 |
| Piotroski F-Score | 4 |